Clinical Trial Update: Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) [Phase 4]

View source ↗

Summary

Phase 4 post-marketing trial in Stage 3-4 chronic kidney disease examined the relationship between plasma FGF23 levels, endothelial dysfunction, and sevelamer u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Sevelamer (sevelamer hydrochloride)

Snippet

Sponsor: Gulhane School of Medicine | Conditions: We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients. | Phase 4 | Status: COMPLETED